Pro-Ripple (XRP) Lawyer Running for US Senate Receives Support From Cardano’s Founder
Charles Hoskinson supported Deaton’s campaign with a maximum contribution: check out the exact amount.
TL;DR
- Elizabeth Warren, known for her critical stance on cryptocurrencies, is challenged by pro-crypto attorney John Deaton in Massachusetts’ 2024 Senate race.
- Deaton’s campaign was backed by Charles Hoskinson – founder of Cardano and a well-known name in the digital asset industry.
Rooting for the Crypto Guy
2024 is an election year in the United States, with the country choosing its next President and Senators. One particular battle – that of the state of Massachusetts – offers to be quite intriguing. The current Senator – Elizabeth Warren – will seek re-election, whereas John Deaton will challenge her reign.
The former has held the position since 2013, winning her previous campaigns with a vast majority. She is also known as one of the harshest critics of the cryptocurrency industry, calling for the implementation of stringent rules and describing the asset class as a “fourth-rate alternative to real currency.”
Deaton stands on the opposite corner as an outspoken advocate of the sector. He is also a prominent attorney representing thousands of XRP investors in Ripple’s lawsuit against the US Securities and Exchange Commission (SEC).
Most recently, Deaton received financial backing from another well-known individual in the cryptocurrency industry – Cardano’s founder, Charles Hoskinson. The latter said he had donated the maximum amount to support the lawyer’s campaign, which, according to state laws, is $3,300.
“We need people willing to take on the establishment against banks writing our laws and destroying the Crypto industry,” Hoskinson added.
What are Deaton’s Chances?
Current Senator Warren is an experienced politician with an established reputation, meaning Deaton will find it hard to emerge victorious.
However, the attorney might be able to win the trust of the people of Massachusetts due to one particular fact. According to a survey conducted last year, the state is among the US regions with the most crypto enthusiasts, and those might prefer his candidacy instead of the naysayer Warren.
If elected in November, Deaton promised to work for the working and middle classes, tackle inflation, solve the migrant crisis, and help “the little guy.”
“I am running for U.S. Senate to continue my life’s mission to shake things up for the people who need it most,” he stated .
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify
In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Crypto prices
More
